Biomarker Testing for Cancer Treatment: What Results Can Tell You

Updated 23 October 2026 · Cancer Point

A headline about one medicine helping several cancers can make it sound as though the same treatment is right for everyone. Biomarker testing explains why the decision is more specific: the characteristics of a cancer can matter as much as the organ where it began.

What does a biomarker test look for?

Biomarkers include changes in genes, proteins and other measurable features of cancer cells. Tests may examine tumour tissue or, in certain situations, a blood sample. Some check one marker; others examine a panel. The National Cancer Institute explains that results can help select a targeted treatment, an immunotherapy or a clinical trial.

This is different from testing whether a person inherited a cancer-related gene change. A tumour result sometimes raises that question, but a separate assessment may be needed. See our guide to inherited cancer risk.

A useful result is not a promise

A matching biomarker may identify a treatment option; it cannot guarantee that the treatment will work. A test can also find no useful treatment match or a change whose significance is uncertain. The oncologist must consider the whole diagnosis, previous treatment and the person's health.

Keep three questions separate: was a marker found, is there evidence for a treatment in this situation, and can that treatment actually be accessed? A laboratory report listing a medicine does not answer all three. Approval and availability in another country do not establish availability in Pakistan.

Before agreeing to testing

Ask the treating team to identify the decision the test is intended to support. This helps turn a broad offer of “advanced testing” into a concrete discussion. Use this appointment note:

• Purpose: Which treatment choice could change after the result?
• Sample: Can the existing biopsy material be used, or is another procedure needed?
• Timing: When should the result arrive, and what is the plan while waiting?
• Total cost: Does the quote include sample handling, transport and explanation of the report?
• Follow-up: Who will discuss a positive, negative or unclear result?

Ask for the laboratory name and a written copy of the test ordered. Keep this with the pathology report so a second clinician can see what was actually examined. Do not arrange duplicate tests simply because different providers use different marketing names.

Reading the report with your clinician

Make two columns on a page: “what the report says” and “what this changes for me.” Copy the exact marker name into the first column. Ask the clinician to complete the second in plain language. If a clinical trial is mentioned, ask about eligibility, travel, extra visits and which costs are covered; a listing is not an offer of enrolment.

If there is no useful match, ask what the next treatment options are. An inconclusive or negative biomarker result does not mean there is no care available. Avoid comparing your result with another person's online report: a similar word can have a different meaning in a different cancer.

The goal is an explained decision, not the largest possible testing package. Bring questions back to the oncology team before changing or delaying treatment.

Editorial update: This guide replaces a dated drug-news article. Older response-rate, approval and price claims have been removed; they should not be used to choose treatment today.

This guide provides general education, not a diagnosis or a personal treatment plan. Discuss medical decisions with a qualified healthcare professional. It has not received an independent clinical review. Read our editorial policy and medical disclaimer.